Invivyd Doses First Participants in Phase 3 LIBERTY Trial for VYD2311; Next-Gen Antibody and Co-Administration Study Underway

What happened

Invivyd announced first participants dosed in its Phase 3 LIBERTY trial evaluating VYD2311, a next-generation monoclonal antibody for COVID-19 prevention, alone and co-administered with an mRNA vaccine. The trial aims to assess safety, tolerability, and immunology, with topline data expected in Q3 2026 alongside pivotal DECLARATION data. While VYD2311 offers a potential improvement in dosing convenience and variant coverage, Invivyd's current revenue from PEMGARDA fell far short of initial expectations at ~$25M in 2024. The company faces significant competitive pressure from AstraZeneca's sipavibart and must demonstrate that its variant-surveillance engine can sustain susceptibility. LIBERTY adds a medium-term catalyst but does not resolve near-term commercial execution risks or the ongoing reliance on EUA continuity.

Implication

Investors should view LIBERTY as a potential catalyst for VYD2311's eventual BLA path, but the study's Q3 2026 timeline offers no near-term relief. Focus remains on PEMGARDA's commercial traction and variant susceptibility, with sipavibart looming. The co-administration arm could differentiate VYD2311 if data are positive, but execution risk is high given past misses.

Thesis delta

The LIBERTY trial initiation shifts the narrative toward VYD2311 as a future growth driver, but near-term thesis remains anchored on PEMGARDA execution and EUA continuity. We see the risk/reward as balanced, pending further data on VYD2311's profile and commercial uptake. The co-administration angle is interesting but unproven.